HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH RSS TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cai, W. Articles by Chen, X. Search for Related Content PubMed PubMed Citation Articles by Cai, W. Articles by Chen, X.

PET Imaging of Colorectal Cancer in Xenograft-Bearing Mice by Use of an ¹⁸F-Labeled T84.66 Anti–Carcinoembryonic Antigen Diabody

¹ Molecular Imaging Program at Stanford (MIPS) and Bio-X Program, Department of Radiology, Stanford University School of Medicine, Stanford, California; ² Crump Institute for Molecular Imaging, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, Los Angeles, California; ³ Department of Bioengineering, Stanford University School of Medicine, Stanford, California; and ⁴ Division of Radiology, City of Hope National Medical Center, Duarte, California

Correspondence: For correspondence or reprints contact: Xiaoyuan Chen, PhD, Molecular Imaging Program at Stanford (MIPS) and Bio-X Program, Department of Radiology, Stanford University School of Medicine, 1201 Welch Rd., P095, Stanford, CA 94305-5484. E-mail: shawchen{at}stanford.edu

In this study, we investigated the ¹⁸F-labeled anti–carcinoembryonic antigen (CEA) T84.66 diabody, a genetically engineered noncovalent dimer of single-chain variable fragments, for small-animal PET imaging of CEA expression in xenograft-bearing mice. Methods: ¹⁸F labeling of the anti-CEA T84.66 diabody (molecular mass, 55 kDa) was achieved with N-succinimidyl-4-¹⁸F-fluorobenzoate (¹⁸F-SFB). The biodistribution of the ¹⁸F-fluorobenzyl-T84.66 diabody (¹⁸F-FB-T84.66 diabody) was evaluated in athymic nude mice bearing subcutaneous LS 174T human colon carcinoma and C6 rat glioma tumors. Serial small-animal PET imaging studies were performed to further evaluate in vivo targeting efficacy and pharmacokinetics. Results: Radiolabeling required 35 ± 5 (mean ± SD) min starting from ¹⁸F-SFB, and the tracer ¹⁸F-FB-T84.66 diabody was synthesized with a specific activity of 1.83 ± 1.71 TBq/mmol. The decay-corrected radiochemical yield was 1.40% ± 0.16% (n = 4), and the radiochemical purity was greater than 98%. The radioimmunoreactivity was 57.1% ± 2.0%. The ¹⁸F-FB-T84.66 diabody showed rapid and high tumor uptake and fast clearance from the circulation in the LS 174T xenograft model, as evidenced by both small-animal PET imaging and biodistribution studies. High-contrast small-animal PET images were obtained as early as 1 h after injection of the ¹⁸F-FB-T84.66 diabody, and only a background level of activity accumulation was found in CEA-negative C6 tumors. The tracer exhibited predominantly renal clearance, with some activity in the liver and spleen at early time points. Conclusion: The ¹⁸F-labeled diabody represents a new class of tumor-specific probes for PET that are based on targeting cell surface antigen expression. The ¹⁸F-FB-T84.66 diabody can be used for high-contrast small-animal PET imaging of CEA-positive tumor xenografts. It may be translated to the clinic for PET of CEA-positive malignancies.

Key Words: carcinoembryonic antigen (CEA) • T84.66 diabody • ¹⁸F • small-animal PET • colorectal cancer

COPYRIGHT © 2007 by the Society of Nuclear Medicine, Inc.

Related articles in JNM:

This Month in JNM

JNM 2007 48: 11a-12a. [Full Text]  

¹⁸F Labeling for Immuno-PET: Where Speed and Contrast Meet

John E. Shively
JNM 2007 48: 170-172. [Full Text]  

This article has been cited by other articles:

				J. V. Leyton, T. Olafsen, M. A. Sherman, K. B. Bauer, P. Aghajanian, R. E. Reiter, and A. M. Wu Engineered humanized diabodies for microPET imaging of prostate stem cell antigen-expressing tumors Protein Eng. Des. Sel., March 1, 2009; 22(3): 209 - 216. [Abstract] [Full Text] [PDF]

				A. M. Wu Antibodies and Antimatter: The Resurgence of Immuno-PET J. Nucl. Med., January 1, 2009; 50(1): 2 - 5. [Abstract] [Full Text] [PDF]

				Q. Cao, W. Cai, G. Niu, L. He, and X. Chen Multimodality Imaging of IL-18-Binding Protein-Fc Therapy of Experimental Lung Metastasis Clin. Cancer Res., October 1, 2008; 14(19): 6137 - 6145. [Abstract] [Full Text] [PDF]

				W. Cai and X. Chen Multimodality Molecular Imaging of Tumor Angiogenesis J. Nucl. Med., June 1, 2008; 49(Suppl_2): 113S - 128S. [Abstract] [Full Text] [PDF]

				Z. Cheng, O. P. De Jesus, M. Namavari, A. De, J. Levi, J. M. Webster, R. Zhang, B. Lee, F. A. Syud, and S. S. Gambhir Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules J. Nucl. Med., May 1, 2008; 49(5): 804 - 813. [Abstract] [Full Text] [PDF]

				R. M. Sharkey, H. Karacay, S. Vallabhajosula, W. J. McBride, E. A. Rossi, C.-H. Chang, S. J. Goldsmith, and D. M. Goldenberg Metastatic Human Colonic Carcinoma: Molecular Imaging with Pretargeted SPECT and PET in a Mouse Model Radiology, February 1, 2008; 246(2): 497 - 507. [Abstract] [Full Text] [PDF]

				G. A.M.S. van Dongen, G. W.M. Visser, M. N. Lub-de Hooge, E. G. de Vries, and L. R. Perk Immuno-PET: A Navigator in Monoclonal Antibody Development and Applications Oncologist, December 1, 2007; 12(12): 1379 - 1389. [Abstract] [Full Text] [PDF]

				W. Cai, K. Chen, Z.-B. Li, S. S. Gambhir, and X. Chen Dual-Function Probe for PET and Near-Infrared Fluorescence Imaging of Tumor Vasculature J. Nucl. Med., November 1, 2007; 48(11): 1862 - 1870. [Abstract] [Full Text] [PDF]

				J. E. Shively 18F Labeling for Immuno-PET: Where Speed and Contrast Meet J. Nucl. Med., February 1, 2007; 48(2): 170 - 172. [Full Text] [PDF]